Problem Solving in Cancer Immunotherapy

• a multidisciplinary review including the latest developments in cancer immunotherapy from over 70 experts and leaders
• hands-on, practical guide to immunotherapy for hospital and community teams, GPs and allied care professionals, including 23 case studies
• a valuable learning tool for doctors, nurses, graduate medical trainees, care managers and anyone involved in cancer care
• produced in partnership with the Association of Cancer Physicians (ACP)

  ---

A broad and experienced team, including medical oncologists and life scientists, have collaborated to produce this practical guide to cancer immunotherapy. It provides a compendium of best practice, including 23 case studies to act as models for professionals to make decisions, either for individual patients or as the basis for using immunotherapy across an organisation, planning area, region or country. As well as introducing all key concepts, expert practitioners provide a guide to future treatments using novel technologies, discuss key problems and suggest solutions, and consider the costs of immunotherapy treatments.

This guide is designed as a handbook for practising clinicians and professionals. It is also an excellent training tool, which will help new teams and clinical staff to align thinking, develop procedures, and adopt best practice.

Chapters

1) Immunotherapy – past, present and future, S Luke Hill and Peter Johnson

2) Beyond Exhausted. Tumour Immune Checkpoints and Their Therapeutic Targets, Joanne Evans and Tom Newsom-Davis

3) Checkpoint inhibitors: where have we come from and where are we going? Elizabeth Appleton and Christy Ralph

4) Immune-related toxicity of checkpoint inhibitors, Lewis Au, James Clark, Jennifer Thomas and James Larkin

5) Predicting Response to Immunotherapy, Ioannis Karydis and Ruth Board

6) Difficulties in assessment of PD-L1 expression, Alexander Haragan and John Gosney

7) Radiological assessment of immunotherapy, Beth Shepherd

8) Combination immunotherapies – multimodality treatment, Paul Nathan

9) The future of novel vaccine strategies in cancer immunotherapy, Peter Selby, Adel Samson, Alan Melcher and Richard Vile

10) Genetically modified cell therapy for solid tumours, Amit Samani, David Marc Davies and Sophie Papa

11) Adoptive cell therapy for haematological malignancies, Charlotte Graham and Reuben Benjamin

12) Tumour Infiltrating Lymphocytes (TILs), Magnus Pedersen, Robert Hawkins and Fiona Thistlethwaite

Cases

1) A case of cytokine release syndrome, Charlotte Graham and Reuben Benjamin

2) High Dose Interleukin- 2 Induced Myocarditis, Manon Pillai and Fiona Thistlethwaite

3) Multiorgan toxicity following combination immunotherapy in melanoma, Jennifer Thomas, Lewis Au and James Larkin

4) Immune-related Endocrine Toxicity Following Immune Checkpoint Inhibitor Therapy, Alec Paschalis and Matthew Wheater

5) Checkpoint Inhibitors in patients with autoimmune disease, Alfred CP So and Ruth Board

6) A patient with Lung Cancer who received an immune checkpoint inhibitor in the first-line setting, Adam Januszewski and Sanjay Popat

7) A Case of Sinonasal Mucosal Melanoma, Anna Olsson-Brown and Joseph Sacco

8) Adjuvant immunotherapy in metastatic melanoma, Helen Adderley and Avinash Gupta

9) Ongoing response after stopping immunotherapy, Zena Salih and Avinash Gupta

10) A case of pneumonitis following treatment with an anti-PD1 antibody in a patient with NSCLC, Claire Storey, Anna Beattie and Alastair Greystoke

11) A case of colitis following combination immunotherapy within a clinical study for Small Cell Lung cancer, Beth Lambourne, John Reicher, Ally Speight and Alastair Greystoke

12) Jaundice after pembrolizumab in a patient with melanoma and brain metastases, Gary Doherty and Pippa Corrie

13) Localised scleroderma as a manifestation of a skin immune-related adverse event in a patient with metastatic melanoma treated with pembrolizumab, Claire M Connell, Sarah J Welsh, Conor Broderick, Marc Wallace and Pippa Corrie

14) Intracranial melanoma response to Combination Ipilimumab and Nivolumab, Rebecca Johnson and Miranda Payne

15) A case of delayed response to immunotherapy in a patient with acral melanoma, Benjamin Pickwell-Smith and Ruth Board

16) A Case of Facial Nerve Palsy in a Patient with Renal Cell Carcinoma Treated with Nivolumab, Alison May Berner, Romaana Mir, Anand Sharma and Paul Nathan

17) A Case of Acute Kidney Injury in a Patient on Combination Immunotherapy for Metastatic Melanoma, Romaana Mir, Alison May Berner, Heather Shaw and Paul D Nathan

18) A Case of Immune Pneumonitis Following Immunotherapy for Metastatic Melanoma, Dan R Muller, Marcus Remer, Sunnya Zarif, Matthew Wheater and Christian Ottensmeier

19) Patient with ureteric TCC on anti-PD1 antibody - complicated by sarcoidosis, Pavlina Spiliopoulou and Rob Jones

20) A case of renal cell carcinoma treated with ipilimumab and nivolumab, Maria Martinez and Balaji Venugopal

21) A case of ocular toxicity from Nivolumab, Andrew Viggars, Satinder Jagdev, Christy Ralph  and Rosalind Stewart

22) A case of multiple immune related toxicities in a patient with breast cancer on a checkpoint inhibitor and chemotherapy, Rachel Broadbent and Andrew M Wardley

23) Oncolytic viral therapy: T-VEC, Maria Marples